Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · Real-Time Price · USD
0.570
+0.068 (13.51%)
Nov 7, 2024, 4:00 PM EST - Market closed
Unicycive Therapeutics Revenue
In the year 2023, Unicycive Therapeutics had annual revenue of $675.00K, down -29.02%.
Revenue (ttm)
$675.00K
Revenue Growth
-29.02%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
14
Market Cap
53.76M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Fortress Biotech | 82.62M |
HOOKIPA Pharma | 52.16M |
Allurion Technologies | 47.59M |
Accelerate Diagnostics | 12.23M |
OncoCyte | 1.02M |
VYNE Therapeutics | 486.00K |
Daxor | 154.21K |
UNCY News
- 10 days ago - Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024 - GlobeNewsWire
- 22 days ago - Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024 - GlobeNewsWire
- 24 days ago - Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024 - GlobeNewsWire
- 4 weeks ago - Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers - GlobeNewsWire
- 6 weeks ago - Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024 - GlobeNewsWire
- 7 weeks ago - Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024 - GlobeNewsWire
- 2 months ago - Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis - GlobeNewsWire